Literature DB >> 30076011

Analysis of 90-day cost for open versus minimally invasive distal pancreatectomy.

Alexander V Fisher1, Sara Fernandes-Taylor2, Jessica R Schumacher2, Jeffrey A Havlena2, Xing Wang2, Elise H Lawson2, Sean M Ronnekleiv-Kelly1, Emily R Winslow1, Sharon M Weber1, Daniel E Abbott3.   

Abstract

BACKGROUND: Minimally invasive distal pancreatectomy (MIDP) is associated with improved peri-operative outcomes compared to the open approach, though cost-effectiveness of MIDP remains unclear.
METHODS: Patients with pancreatic tumors undergoing open (ODP), robotic (RDP), or laparoscopic distal pancreatectomy (LDP) between 2012-2014 were identified through the Truven Health MarketScan® Database. Median costs (payments) for the index operation and 90-day readmissions were calculated. Multivariable regression was used to predict associations with log 90-day payments.
RESULTS: 693 patients underwent ODP, 146 underwent LDP, and 53 RDP. Compared to ODP, LDP and RDP resulted in shorter median length of stay (6 d. ODP vs. 5 d. RDP vs. 4 d. LDP, p<0.01) and lower median payments ($38,350 ODP vs. $34,870 RDP vs. $32,148 LDP, p<0.01) during the index hospitalization. Total median 90-day payments remained significantly lower for both minimally invasive approaches ($40,549 ODP vs. $35,160 RDP vs. $32,797 LDP, p<0.01). On multivariable analysis, LDP and RDP resulted in 90-day cost savings of 21% and 25% relative to ODP, equating to an amount of $8,500-$10,000.
CONCLUSION: MIDP is associated with >$8,500 in lower cost compared to the open approach. Quality improvement initiatives in DP should ensure that lack of training and technical skill are not barriers to MIDP.
Copyright © 2018 International Hepato-Pancreato-Biliary Association Inc. Published by Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2018        PMID: 30076011     DOI: 10.1016/j.hpb.2018.07.003

Source DB:  PubMed          Journal:  HPB (Oxford)        ISSN: 1365-182X            Impact factor:   3.647


  6 in total

Review 1.  International consensus statement on robotic pancreatic surgery.

Authors:  Rong Liu; Go Wakabayashi; Chinnusamy Palanivelu; Allan Tsung; Kehu Yang; Brian K P Goh; Charing Ching-Ning Chong; Chang Moo Kang; Chenghong Peng; Eli Kakiashvili; Ho-Seong Han; Hong-Jin Kim; Jin He; Jae Hoon Lee; Kyoichi Takaori; Marco Vito Marino; Shen-Nien Wang; Tiankang Guo; Thilo Hackert; Ting-Shuo Huang; Yiengpruksawan Anusak; Yuman Fong; Yuichi Nagakawa; Yi-Ming Shyr; Yao-Ming Wu; Yupei Zhao
Journal:  Hepatobiliary Surg Nutr       Date:  2019-08       Impact factor: 7.293

2.  The laparoscopic approach to distal pancreatectomy is a value-added proposition for patients undergoing care in moderate-volume and high-volume centers.

Authors:  Emanuel Eguia; Paul C Kuo; Patrick Sweigert; Marc Nelson; Gerard V Aranha; Gerard Abood; Constantine V Godellas; Marshall S Baker
Journal:  Surgery       Date:  2019-05-31       Impact factor: 3.982

3.  The issue of the cost of robotic distal pancreatectomies.

Authors:  Benedetto Ielpo; Javier Nuñez-Alfonsel; Maria Victoria Diago; Álvaro Hidalgo; Yolanda Quijano; Emilio Vicente
Journal:  Hepatobiliary Surg Nutr       Date:  2019-12       Impact factor: 7.293

4.  The oncological safety in minimally invasive versus open distal pancreatectomy for pancreatic ductal adenocarcinoma: a systematic review and meta-analysis.

Authors:  Du-Jiang Yang; Jun-Jie Xiong; Hui-Min Lu; Yi Wei; Ling Zhang; Shan Lu; Wei-Ming Hu
Journal:  Sci Rep       Date:  2019-02-04       Impact factor: 4.379

5.  Robotic versus open pancreatic surgery: a propensity score-matched cost-effectiveness analysis.

Authors:  Christian Benzing; Lea Timmermann; Thomas Winklmann; Lena Marie Haiden; Karl Herbert Hillebrandt; Axel Winter; Max Magnus Maurer; Matthäus Felsenstein; Felix Krenzien; Moritz Schmelzle; Johann Pratschke; Thomas Malinka
Journal:  Langenbecks Arch Surg       Date:  2022-03-21       Impact factor: 2.895

6.  Clinical value and cost-effectiveness of minimally invasive distal pancreatectomy.

Authors:  Andrea Belli; Francesco Izzo; Giulio Belli
Journal:  Hepatobiliary Surg Nutr       Date:  2020-04       Impact factor: 7.293

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.